Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 26 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

54%

14 trials in Phase 3/4

Results Transparency

7%

1 of 14 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 4
8(47.1%)
Phase 3
6(35.3%)
N/A
3(17.6%)
17Total
Phase 4(8)
Phase 3(6)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT07476508Not ApplicableCompleted

"Intra-articular Hyaluronic Acid Injection for Accelerating Functional Recovery After Knee Arthroscopy"

Role: lead

NCT07231939Recruiting

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

Role: lead

NCT07203846Phase 4Not Yet Recruiting

Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

Role: lead

NCT05905965Phase 3Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment

Role: lead

NCT04442919Phase 4Completed

Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris

Role: lead

NCT04476173Phase 3Unknown

ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction

Role: lead

NCT04941105Phase 3Completed

Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19

Role: lead

NCT04718025Phase 3Unknown

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

Role: lead

NCT03251859Phase 3Completed

Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study

Role: lead

NCT05779059Phase 3Unknown

Prasugrel Or Ticagrelor De-escalation in NSTE-ACS

Role: lead

NCT05162456Unknown

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation

Role: lead

NCT05109585Unknown

Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study

Role: lead

NCT02772640Phase 4Completed

Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe

Role: lead

NCT03454841Completed

Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor

Role: lead

NCT03074604Not ApplicableCompleted

Carbon Dioxide Surgical Field Flooding and Aortic No-touch Off-pump Coronary Artery Bypass Grafting to Reduce Neurological Injuries After Surgical Coronary Revascularization (CANON): a Randomised, Controlled, Investigator and Patient Blinded Single Center Superiority Trial With Three Parallel Arms.

Role: lead

NCT03493256Completed

Novel BIochemical Markers for Predicting Type 2 NEurological Complications of Surgical Coronary Revascularization (BINER)

Role: lead

NCT02939248Phase 4Completed

Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine

Role: lead

NCT02939235Phase 4Completed

Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine

Role: lead

NCT03764722Phase 4Unknown

Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations

Role: lead

NCT02217878Phase 4Completed

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction

Role: lead